Clinical Trials Logo

BRAF Gene Mutation clinical trials

View clinical trials related to BRAF Gene Mutation.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03088176 Active, not recruiting - Melanoma Clinical Trials

Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma

Start date: June 25, 2017
Phase: Phase 1
Study type: Interventional

The purpose of the study is to determine safety and tolerability of the combination of talimogene laherparepvec in combination with dabrafenib and trametinib in BRAF mutated advanced melanoma.

NCT ID: NCT03049618 Active, not recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.

NCT ID: NCT02925689 Active, not recruiting - Renal Failure Clinical Trials

Dabrafenib in Treating Patients With Solid Tumors and Kidney or Liver Dysfunction

Start date: August 2013
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of dabrafenib in treating patients with solid tumors and kidney or liver dysfunction. Dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.